Tag: daraxonrasib
Beyond the Breakthrough: Pancreatic Cancer Researchers Warn Real Work Is Just Beginning
A new STAT News commentary warns that while breakthrough pancreatic cancer drugs offer promise, the real work—building healthcare infrastructure, establishing…
Breakthrough Drug Targeting ‘Undruggable’ KRAS Mutation Nearly Doubles Pancreatic Cancer Survival
New targeted therapy daraxonrasib successfully inhibits KRAS mutations in pancreatic cancer, nearly doubling survival times. Clinical trial shows 60% reduction…
Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access
Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations. FDA submission planned as five-year pancreatic cancer survival…
New Drug Daraxonrasib Nearly Doubles Pancreatic Cancer Survival in Phase 3 Trial
Daraxonrasib nearly doubles survival in advanced pancreatic cancer patients with KRAS G12C mutations. The breakthrough targets a previously "undruggable" protein…
New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial
A phase 2 trial published in NEJM shows promise for daraxonrasib, a novel targeted therapy for previously treated metastatic pancreatic…